cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2024-4086WZQZCKcardiovascular-4086Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАCORONARY HEART DISEASEАссоциация уровней микроРНК плазмы крови с различной выраженностью коллатерального кровообращения при хронической окклюзии коронарной артерии у пациентов с ишемической болезнью сердца: пилотное исследованиеAssociation of plasma microRNA levels with different collateral circulation degree in chronic total occlusion patients with coronary artery disease: a pilot studyhttps://orcid.org/0000-0003-4765-8021КиселеваА. В.KiselevaA. V.

Киселева Анна Витальевна — к.б.н., в.н.с., руководитель лаборатории молекулярной генетики Института персонализированной терапии и профилактики.

Москва

Moscow

sanyutabe@gmail.comhttps://orcid.org/0000-0003-2602-5006ВасильевД. К.VasilyevD. K.

Васильев Дмитрий Константинович — к.м.н., руководитель отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний.

Москва

Moscow

vasilyevdk@gmail.comhttps://orcid.org/0000-0003-0703-146XСопленковаА. Г.SoplenkovaA. G.

Сопленкова Анна Глебовна — лаборант лаборатории биостатистики отдела эпидемиологии хронических неинфекционных заболеваний.

Москва

Moscow

anna.mail10@mail.ruhttps://orcid.org/0000-0001-7307-1502ШукуровФ. Б.ShukurovF. B.

Шукуров Фирдавс Баходурович — к.м.н., руководитель лаборатории интервенционной радиологии отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний.

Москва

Moscow

FShukurov@gnicpm.ruhttps://orcid.org/0000-0002-8395-4146СотниковаЕ. А.SotnikovaE. A.

Сотникова Евгения Андреевна — с.н.с. лаборатории молекулярной генетики Института персонализированной терапии и профилактики.

Москва

Moscow

sotnikova.evgeniya@gmail.comhttps://orcid.org/0000-0003-3851-4544ФещенкоД. А.FeshchenkoD. A.

Фещенко Дарья Анатольевна — н.с. отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний.

Москва

Moscow

DFeshenko@gnicpm.ruhttps://orcid.org/0000-0001-9844-3122КуценкоВ. А.KutsenkoV. A.

Куценко Владимир Александрович — к.ф.-м.н., с.н.с. лаборатории биостатистики отдела эпидемиологии хронических неинфекционных заболеваний.

Москва

Moscow

vlakutsenko@ya.ruhttps://orcid.org/0000-0002-7294-7274АраблинскийН. А.ArablinskyN. A.

Араблинский Никита Александрович — м.н.с. отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний.

Москва

Moscow

NArablinskiy@gnicpm.ruhttps://orcid.org/0000-0003-3755-0279СкиркоО. П.SkirkoO. P.

Скирко Ольга Петровна — м.н.с. лаборатории молекулярной генетики Института персонализированной терапии и профилактики.

Москва

Moscow

ops_70@mail.ruhttps://orcid.org/0000-0003-0723-0493ЖариковаА. А.ZharikovaA. A.

Жарикова Анастасия Александровна — к.б.н., в.н.с. лаборатории молекулярной генетики Института персонализированной терапии и профилактики, старший преподаватель факультета биоинженерии и биоинформатики.

Москва

Moscow

azharikova89@gmail.comhttps://orcid.org/0000-0001-7989-0760ЕршоваА. И.ErshovaA. I.

Ершова Александра Игоревна — д.м.н., руководитель лаборатории клиномики, зам. директора по фундаментальной науке.

Москва

Moscow

alersh@mail.ruhttps://orcid.org/0000-0001-6985-7131ПокровскаяМ. С.PokrovskayaM. S.

Покровская Мария Сергеевна — к.б.н., в.н.с. лаборатории "Банк биологического материала" Института персонализированной терапии и профилактики.

Москва

Moscow

mpokrovskaia@list.ruhttps://orcid.org/0000-0001-5989-6233МешковА. Н.MeshkovA. N.

Мешков Алексей Николаевич — д.м.н., руководитель Института персонализированной терапии и профилактики.

Москва

Moscow

meshkov@lipidclinic.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна — д.м.н., профессор, академик РАН, директор.

Москва

Moscow

ODrapkina@gnicpm.ruФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России; ФГБОУ ВО "Московский государственный университет им. М.В. Ломоносова"National Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State University20242906202423740864086Copyright © Киселева А.В., Васильев Д.К., Сопленкова А.Г., Шукуров Ф.Б., Сотникова Е.А., Фещенко Д.А., Куценко В.А., Араблинский Н.А., Скирко О.П., Жарикова А.А., Ершова А.И., Покровская М.С., Мешков А.Н., Драпкина О.М., 20242024Киселева А.В., Васильев Д.К., Сопленкова А.Г., Шукуров Ф.Б., Сотникова Е.А., Фещенко Д.А., Куценко В.А., Араблинский Н.А., Скирко О.П., Жарикова А.А., Ершова А.И., Покровская М.С., Мешков А.Н., Драпкина О.М.Kiseleva A.V., Vasilyev D.K., Soplenkova A.G., Shukurov F.B., Sotnikova E.A., Feshchenko D.A., Kutsenko V.A., Arablinsky N.A., Skirko O.P., Zharikova A.A., Ershova A.I., Pokrovskaya M.S., Meshkov A.N., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/4086Цель

Цель. Изучение ассоциации 9 микроРНК плазмы крови и выраженности коллатерального кровообращения (КК) при наличии хронической окклюзии коронарной артерии (ХОКА) у пациентов с ишемической болезнью сердца (ИБС).

Материал и методы

Материал и методы. Измерение уровня экспрессии 9 циркулирующих микроРНК в плазме было проведено с помощью полимеразной цепной реакции в режиме реального времени с использованием технологии Taqman на выборке из 43 человек. В исследование были включены пациенты с ИБС и ХОКА с хорошо (n=13) или плохо (n=10) развитым КК на основе классификации Rentrop, а также контрольная группа пациентов без значимого стенозирования коронарных артерий (n=20).

Результаты

Результаты. Статистически значимые различия в уровне экспрессии были получены для 7 циркулирующих микроРНК у пациентов с ХОКА и хорошим КК и для 5 микроРНК в общей группе пациентов с ХОКА по сравнению с контрольной группой. Из 7 микроРНК была выявлена сниженная экспрессия hsa-miR-126-5p, hsa-miR-146a-5p, hsa-miR-155-5p, hsa-miR-15b-5p, hsa-miR-21-5p, hsa-miR-23a-3p и повышенная экспрессия hsa-miR-451a. Впервые показано, что уровень 2-х микроРНК (hsa-miR-23a-3p, hsa-miR-21-5p) существенно снижен, а уровень hsa-miR-451a повышен у пациентов с ИБС с достаточной функцией коллатеральных артерий.

Заключение

Заключение. МикроРНК плазмы, для которых были получены статистически значимые различия, могут быть использованы для дальнейших исследований на выборке большего размера как кандидаты в биомаркеры для оценки выраженности КК при наличии ХОКА.

Aim

Aim. To investigate the association of 10 circulating plasma microRNAs with collateral flow degree in chronic total occlusion (CTO) patients with coronary artery disease (CAD).

Materials and methods

Materials and methods. Plasma expression levels of 10 circulating miRNAs were measured by real-time PCR using Taqman technology in a sample of 43 subjects. The study included patients with CAD and CTO with good (n=13) or poor (n=10) coronary collateral circulation (CCC) based on Rentrop classification and a control group of patients without significant coronary stenosis (n=20).

Results

Results. Significant differences in expression levels were found for 7 circulating miRNAs in patients with CTO and good CCC and for 5 microRNAs in the combined group of patients with CTO compared to the control group. Among the 7 microRNAs, decreased expression of hsa-miR-126-5p, hsa-miR-146a-5p, hsa-miR-155-5p, hsa-miR-15b-5p, hsa-miR-21-5p, hsa-miR-23a-3p and increased expression of hsa-miR-451a were detected. For the first time, we showed that the level of 2 microRNAs (hsa-miR-23a-3p, hsa-miR-21-5p) is significantly reduced and the level of hsa-miR-451a is increased in patients with CAD with good CCC.

Conclusion

Conclusion. Plasma microRNAs with significant differences obtained can be used for further studies on a larger sample size as candidate biomarkers for assessing the severity of ССС in the presence of CTO.

ишемическая болезнь сердцамикроРНКхроническая окклюзия коронарной артериикоронарное коллатеральное кровообращениеcoronary artery diseasemicroRNAchronic total occlusioncoronary collateral circulationReferencesLi Y, Xue J-Y, Chen S, et al. LncRNA PVT1 is a novel mediator promoting the angiogenesis response associated with collateral artery formation. Int J Biochem Cell Biol. 2022;151:106294. doi:10.1016/j.biocel.2022.106294.Li Y, Xue J-Y, Chen S, et al. LncRNA PVT1 is a novel mediator promoting the angiogenesis response associated with collateral artery formation. Int J Biochem Cell Biol. 2022;151:106294. doi:10.1016/j.biocel.2022.106294.Hakimzadeh N, Nossent AY, van der Laan AM, et al. Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS One. 2015;10:e0137035. doi:10.1371/journal.pone.0137035.Hakimzadeh N, Nossent AY, van der Laan AM, et al. Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS One. 2015;10:e0137035. doi:10.1371/journal.pone.0137035.Zhu L-P, Zhou J-P, Zhang J-X, et al. MiR-15b-5p Regulates Collateral Artery Formation by Targeting AKT3 (Protein Kinase B-3). Arterioscler Thromb Vasc Biol. 2017;37:957-68. doi:10.1161/ATVBAHA.116.308905.Zhu L-P, Zhou J-P, Zhang J-X, et al. MiR-15b-5p Regulates Collateral Artery Formation by Targeting AKT3 (Protein Kinase B-3). Arterioscler Thromb Vasc Biol. 2017;37:957-68. doi:10.1161/ATVBAHA.116.308905.Elsman P, van ’t Hof AWJ, de Boer MJ, et al. Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J. 2004;25:854-8. doi:10.1016/j.ehj.2004.03.005.Elsman P, van ’t Hof AWJ, de Boer MJ, et al. Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J. 2004;25:854-8. doi:10.1016/j.ehj.2004.03.005.Wang J, Yan Y, Song D, et al. Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease. Biomed Res Int. 2016;2016:4285942. doi:10.1155/2016/4285942.Wang J, Yan Y, Song D, et al. Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease. Biomed Res Int. 2016;2016:4285942. doi:10.1155/2016/4285942.Schirmer SH, Fledderus JO, Bot PTG, et al. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res. 2008;102:1286-94. doi:10.1161/CIRCRESAHA.108.171827.Schirmer SH, Fledderus JO, Bot PTG, et al. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res. 2008;102:1286-94. doi:10.1161/CIRCRESAHA.108.171827.Fazmin IT, Achercouk Z, Edling CE, et al. Circulating microRNA as a Biomarker for Coronary Artery Disease. Biomolecules. 2020;10. doi:10.3390/biom10101354.Fazmin IT, Achercouk Z, Edling CE, et al. Circulating microRNA as a Biomarker for Coronary Artery Disease. Biomolecules. 2020;10. doi:10.3390/biom10101354.Hans FP, Moser M, Bode C, et al. MicroRNA regulation of angiogenesis and arteriogenesis. Trends Cardiovasc Med. 2010; 20:253-62. doi:10.1016/j.tcm.2011.12.001.Hans FP, Moser M, Bode C, et al. MicroRNA regulation of angiogenesis and arteriogenesis. Trends Cardiovasc Med. 2010; 20:253-62. doi:10.1016/j.tcm.2011.12.001.Bergami M, Fabin N, Cenko E, et al. MicroRNAs as Potential Biomarkers in Coronary Artery Disease. Curr Top Med Chem. 2023; 23:454-69. doi:10.2174/1568026623666221221124530.Bergami M, Fabin N, Cenko E, et al. MicroRNAs as Potential Biomarkers in Coronary Artery Disease. Curr Top Med Chem. 2023; 23:454-69. doi:10.2174/1568026623666221221124530.Fei Y, Hou J, Xuan W, et al. The relationship of plasma miR-503 and coronary collateral circulation in patients with coronary artery disease. Life Sci. 2018;207:145-51. doi:10.1016/j.lfs.2018.06.001.Fei Y, Hou J, Xuan W, et al. The relationship of plasma miR-503 and coronary collateral circulation in patients with coronary artery disease. Life Sci. 2018;207:145-51. doi:10.1016/j.lfs.2018.06.001.Nie X, Su L, Zhou Y, et al. Association between plasma levels of microRNA-126 and coronary collaterals in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42:561-5.Nie X, Su L, Zhou Y, et al. Association between plasma levels of microRNA-126 and coronary collaterals in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42:561-5.Han H, Qu G, Han C, et al. MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort. Exp Mol Med. 2015;47:e138. doi:10.1038/emm.2014.81.Han H, Qu G, Han C, et al. MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort. Exp Mol Med. 2015;47:e138. doi:10.1038/emm.2014.81.Zhou Q, Gallagher R, Ufret-Vincenty R, et al. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc Natl Acad Sci USA. 2011;108:8287-92. doi:10.1073/pnas.1105254108.Zhou Q, Gallagher R, Ufret-Vincenty R, et al. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc Natl Acad Sci USA. 2011;108:8287-92. doi:10.1073/pnas.1105254108.Ferguson SW, Wang J, Lee CJ, et al. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci Rep. 2018;8:1419. doi:10.1038/s41598-018-19581-x.Ferguson SW, Wang J, Lee CJ, et al. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci Rep. 2018;8:1419. doi:10.1038/s41598-018-19581-x.Kura B, Kalocayova B, Devaux Y, et al. Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection. Int J Mol Sci. 2020;21. doi:10.3390/ijms21030700.Kura B, Kalocayova B, Devaux Y, et al. Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection. Int J Mol Sci. 2020;21. doi:10.3390/ijms21030700.Chang W-T, Lin Y-W, Huang P-S, et al. Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench. Front Cardiovasc Med. 2022;9:826478. doi:10.3389/fcvm.2022.826478.Chang W-T, Lin Y-W, Huang P-S, et al. Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench. Front Cardiovasc Med. 2022;9:826478. doi:10.3389/fcvm.2022.826478.Liu J, Wang Y, Akamatsu Y, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol. 2014;115:138-56. doi:10.1016/j.pneurobio.2013.11.004.Liu J, Wang Y, Akamatsu Y, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol. 2014;115:138-56. doi:10.1016/j.pneurobio.2013.11.004.Wu F, Yang Z, Li G. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun. 2009;386:549-53. doi:10.1016/j.bbrc.2009.06.075.Wu F, Yang Z, Li G. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun. 2009;386:549-53. doi:10.1016/j.bbrc.2009.06.075.Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5:587-92. doi:10.1016/s0735-1097(85)80380-6.Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5:587-92. doi:10.1016/s0735-1097(85)80380-6.Khoo V, Shen L, Zhao L, et al. Determination of the severity of underlying lesions in acute myocardial infarction on the basis of collateral vessel development. Coron Artery Dis. 2014;25:493-7. doi:10.1097/MCA.0000000000000115.Khoo V, Shen L, Zhao L, et al. Determination of the severity of underlying lesions in acute myocardial infarction on the basis of collateral vessel development. Coron Artery Dis. 2014;25:493-7. doi:10.1097/MCA.0000000000000115.Копылова О. В., Ершова А. И., Покровская М. С. и др. Популяционно-нозологический исследовательский биобанк "НМИЦ ТПМ": анализ коллекций биообразцов, принципы сбора и хранения информации. Кардиоваскулярная терапия и профилактика. 2021;20(8):3119. doi:10.15829/1728-8800-2021-3119.Kopylova OV, Ershova AI, Pokrovskaya MS, et al. Population-nosological research biobank of the National Medical Research Center for Therapy and Preventive Medicine: analysis of biosamples, principles of collecting and storing information. Cardiovascular Therapy and Prevention. 2021;20(8):3119. (In Russ.) doi:10.15829/1728-8800-2021-3119.Wang J, Yan Y, Song D, et al. The association of plasma miR-155 and VCAM-1 levels with coronary collateral circulation. Biomark Med. 2017;11:125-31. doi:10.2217/bmm-2016-0282.Wang J, Yan Y, Song D, et al. The association of plasma miR-155 and VCAM-1 levels with coronary collateral circulation. Biomark Med. 2017;11:125-31. doi:10.2217/bmm-2016-0282.Zhelankin AV, Vasiliev SV, Stonogina DA, et al. Elevated Plasma Levels of Circulating Extracellular miR-320a-3p in Patients with Paroxysmal Atrial Fibrillation. Int J Mol Sci. 2020;21. doi:10.3390/ijms21103485.Zhelankin AV, Vasiliev SV, Stonogina DA, et al. Elevated Plasma Levels of Circulating Extracellular miR-320a-3p in Patients with Paroxysmal Atrial Fibrillation. Int J Mol Sci. 2020;21. doi:10.3390/ijms21103485.Li S, Lee C, Song J, et al. Circulating microRNAs as potential biomarkers for coronary plaque rupture. Oncotarget. 2017;8:48145-56. doi:10.18632/oncotarget.18308.Li S, Lee C, Song J, et al. Circulating microRNAs as potential biomarkers for coronary plaque rupture. Oncotarget. 2017;8:48145-56. doi:10.18632/oncotarget.18308.Wong LM, Phoon LQ, Wei LK. Epigenetics Modifications in Large-Artery Atherosclerosis: A Systematic Review. J Stroke Cerebrovasc Dis. 2021;30:106033. doi:10.1016/j.jstrokecerebrovasdis.2021.106033.Wong LM, Phoon LQ, Wei LK. Epigenetics Modifications in Large-Artery Atherosclerosis: A Systematic Review. J Stroke Cerebrovasc Dis. 2021;30:106033. doi:10.1016/j.jstrokecerebrovasdis.2021.106033.Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59:S1-6. doi:10.1016/j.ymeth.2012.09.015.Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59:S1-6. doi:10.1016/j.ymeth.2012.09.015.Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25:402-8. doi:10.1006/meth.2001.1262.Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25:402-8. doi:10.1006/meth.2001.1262.Nik Mohamed Kamal NNSB, Shahidan WNS. Non-Exosomal and Exosomal Circulatory MicroRNAs: Which Are More Valid as Biomarkers? Front Pharmacol. 2019;10:1500. doi:10.3389/fphar.2019.01500.Nik Mohamed Kamal NNSB, Shahidan WNS. Non-Exosomal and Exosomal Circulatory MicroRNAs: Which Are More Valid as Biomarkers? Front Pharmacol. 2019;10:1500. doi:10.3389/fphar.2019.01500.de Gonzalo-Calvo D, Pérez-Boza J, Curado J, et al. Challenges of microRNA-based biomarkers in clinical application for cardiovascular diseases. Clin Transl Med. 2022;12:e585. doi:10.1002/ctm2.585.de Gonzalo-Calvo D, Pérez-Boza J, Curado J, et al. Challenges of microRNA-based biomarkers in clinical application for cardiovascular diseases. Clin Transl Med. 2022;12:e585. doi:10.1002/ctm2.585.Li J, Li K, Chen X. Inflammation-regulatory microRNAs: Valuable targets for intracranial atherosclerosis. J Neurosci Res. 2019;97: 1242-52. doi:10.1002/jnr.24487.Li J, Li K, Chen X. Inflammation-regulatory microRNAs: Valuable targets for intracranial atherosclerosis. J Neurosci Res. 2019;97: 1242-52. doi:10.1002/jnr.24487.Chu T, Xu X, Ruan Z, et al. miR-146a contributes to atherosclerotic plaque stability by regulating the expression of TRAF6 and IRAK-1. Mol Biol Rep. 2022;49:4205-16. doi:10.1007/s11033-022-07253-z.Chu T, Xu X, Ruan Z, et al. miR-146a contributes to atherosclerotic plaque stability by regulating the expression of TRAF6 and IRAK-1. Mol Biol Rep. 2022;49:4205-16. doi:10.1007/s11033-022-07253-z.Xiong X-D, Cho M, Cai X-P, et al. A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. Mutat Res. 2014;761:15-20. doi:10.1016/j.mrfmmm.2014.01.001.Xiong X-D, Cho M, Cai X-P, et al. A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. Mutat Res. 2014;761:15-20. doi:10.1016/j.mrfmmm.2014.01.001.Chang T-Y, Tsai W-C, Huang T-S, et al. Dysregulation of endothelial colony-forming cell function by a negative feedback loop of circulating miR-146a and -146b in cardiovascular disease patients. PLoS One. 2017;12:e0181562. doi:10.1371/journal.pone.0181562.Chang T-Y, Tsai W-C, Huang T-S, et al. Dysregulation of endothelial colony-forming cell function by a negative feedback loop of circulating miR-146a and -146b in cardiovascular disease patients. PLoS One. 2017;12:e0181562. doi:10.1371/journal.pone.0181562.Ghafouri-Fard S, Gholipour M, Taheri M. Role of MicroRNAs in the Pathogenesis of Coronary Artery Disease. Front Cardiovasc Med. 2021;8:632392. doi:10.3389/fcvm.2021.632392.Ghafouri-Fard S, Gholipour M, Taheri M. Role of MicroRNAs in the Pathogenesis of Coronary Artery Disease. Front Cardiovasc Med. 2021;8:632392. doi:10.3389/fcvm.2021.632392.Huang S-F, Zhao G, Peng X-F, et al. The Pathogenic Role of Long Non-coding RNA H19 in Atherosclerosis via the miR-146a-5p/ANGPTL4 Pathway. Front Cardiovasc Med. 2021;8:770163. doi:10.3389/fcvm.2021.770163.Huang S-F, Zhao G, Peng X-F, et al. The Pathogenic Role of Long Non-coding RNA H19 in Atherosclerosis via the miR-146a-5p/ANGPTL4 Pathway. Front Cardiovasc Med. 2021;8:770163. doi:10.3389/fcvm.2021.770163.Gao W, Li R, Yu J, et al. LncRNA SCIRT is downregulated in atherosclerosis and suppresses the proliferation of human aortic smooth muscle cells (HAOSMCs) by sponging miR-146a in cytoplasm. J Cardiothorac Surg. 2021;16:324. doi:10.1186/s13019-021-01700-x.Gao W, Li R, Yu J, et al. LncRNA SCIRT is downregulated in atherosclerosis and suppresses the proliferation of human aortic smooth muscle cells (HAOSMCs) by sponging miR-146a in cytoplasm. J Cardiothorac Surg. 2021;16:324. doi:10.1186/s13019-021-01700-x.Zhelankin AV, Stonogina DA, Vasiliev SV, et al. Circulating Extracellular miRNA Analysis in Patients with Stable CAD and Acute Coronary Syndromes. Biomolecules. 2021;11. doi:10.3390/biom11070962.Zhelankin AV, Stonogina DA, Vasiliev SV, et al. Circulating Extracellular miRNA Analysis in Patients with Stable CAD and Acute Coronary Syndromes. Biomolecules. 2021;11. doi:10.3390/biom11070962.Rizzacasa B, Morini E, Mango R, et al. MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study. PLoS One. 2019;14:e0216363. doi:10.1371/journal.pone.0216363.Rizzacasa B, Morini E, Mango R, et al. MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study. PLoS One. 2019;14:e0216363. doi:10.1371/journal.pone.0216363.Pereira-da-Silva T, Napoleão P, Costa MC, et al. Circulating miRNAs Are Associated with the Systemic Extent of Atherosclerosis: Novel Observations for miR-27b and miR-146. Diagnostics (Basel). 2021;11. doi:10.3390/diagnostics11020318.Pereira-da-Silva T, Napoleão P, Costa MC, et al. Circulating miRNAs Are Associated with the Systemic Extent of Atherosclerosis: Novel Observations for miR-27b and miR-146. Diagnostics (Basel). 2021;11. doi:10.3390/diagnostics11020318.Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261-71. doi:10.1016/j.devcel.2008.07.002.Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261-71. doi:10.1016/j.devcel.2008.07.002.Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810-17. doi:10.1161/CIRCRESAHA.110.226357.Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810-17. doi:10.1161/CIRCRESAHA.110.226357.Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677-84. doi:10.1161/CIRCRESAHA.109.215566.Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677-84. doi:10.1161/CIRCRESAHA.109.215566.Wang X, Lian Y, Wen X, et al. Expression of miR-126 and its potential function in coronary artery disease. Afr Health Sci. 2017;17:474-80. doi:10.4314/ahs.v17i2.22.Wang X, Lian Y, Wen X, et al. Expression of miR-126 and its potential function in coronary artery disease. Afr Health Sci. 2017;17:474-80. doi:10.4314/ahs.v17i2.22.Ren J, Zhang J, Xu N, et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One. 2013;8:e80738. doi:10.1371/journal.pone.0080738.Ren J, Zhang J, Xu N, et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One. 2013;8:e80738. doi:10.1371/journal.pone.0080738.Xue S, Liu D, Zhu W, et al. Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p Are Novel Biomarkers for Diagnosis of Acute Myocardial Infarction. Front Physiol. 2019;10:123. doi:10.3389/fphys.2019.00123.Xue S, Liu D, Zhu W, et al. Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p Are Novel Biomarkers for Diagnosis of Acute Myocardial Infarction. Front Physiol. 2019;10:123. doi:10.3389/fphys.2019.00123.Su M, Niu Y, Dang Q, et al. Circulating microRNA profiles based on direct S-Poly(T)Plus assay for detection of coronary heart disease. J Cell Mol Med. 2020;24:5984-97. doi:10.1111/jcmm.15001.Su M, Niu Y, Dang Q, et al. Circulating microRNA profiles based on direct S-Poly(T)Plus assay for detection of coronary heart disease. J Cell Mol Med. 2020;24:5984-97. doi:10.1111/jcmm.15001.Zhu Y, Yang T, Duan J, et al. MALAT1/miR-15b-5p/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway. Aging. 2019;11:1089-109. doi:10.18632/aging.101766.Zhu Y, Yang T, Duan J, et al. MALAT1/miR-15b-5p/MAPK1 mediates endothelial progenitor cells autophagy and affects coronary atherosclerotic heart disease via mTOR signaling pathway. Aging. 2019;11:1089-109. doi:10.18632/aging.101766.Knoka E, Trusinskis K, Mazule M, et al. Circulating plasma microRNA-126, microRNA-145, and microRNA-155 and their association with atherosclerotic plaque characteristics. Transl Res. 2020;5:60-7. doi:10.18053/jctres.05.201902.002.Knoka E, Trusinskis K, Mazule M, et al. Circulating plasma microRNA-126, microRNA-145, and microRNA-155 and their association with atherosclerotic plaque characteristics. Transl Res. 2020;5:60-7. doi:10.18053/jctres.05.201902.002.Weber M, Baker MB, Patel RS, et al. MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract. 2011;2011:532915. doi:10.4061/2011/532915.Weber M, Baker MB, Patel RS, et al. MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract. 2011;2011:532915. doi:10.4061/2011/532915.Faccini J, Ruidavets J-B, Cordelier P, et al. Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease. Sci Rep. 2017;7:42916. doi:10.1038/srep42916.Faccini J, Ruidavets J-B, Cordelier P, et al. Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease. Sci Rep. 2017;7:42916. doi:10.1038/srep42916.Huică I, Iancu I, Botezatu A, et al. Circulating miR-21 and TGF-b1 expression levels in patients with cardiovascular diseases. Transl Res. 2015;20:132. doi:10.21614/JTMR-20-3-44.Huică I, Iancu I, Botezatu A, et al. Circulating miR-21 and TGF-b1 expression levels in patients with cardiovascular diseases. Transl Res. 2015;20:132. doi:10.21614/JTMR-20-3-44.

The authors declare that there are no conflicts of interest present.